'Truly innovative' drugs not a priority for pricing probes, top EU antitrust official says
High-impact, novel drugs are not the best target for EU antitrust enforcers concerned by ripoff prices in the pharmaceutical sector, according to a senior European Commission official. Others, in particular legislators,...To view the full article, register now.
Already a subscriber? Click here to view full article